Ferring extends commercial links with Kyowa Kirin in Japan
This article was originally published in Scrip
Ferring has opted to tie up with existing partner Kyowa Hakko Kirin for the co-promotion in Japan of a line extension for desmopressin acetate hydrate, in a deal that should strengthen the Swiss group's commercial activities in this market.
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.